Page last updated: 2024-11-08

cassine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cassine: RN given for (2S-(2alpha,5alpha,6alpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
CassinegenusRN given for (2S-(2alpha,5alpha,6alpha))-isomer[MeSH]CelastraceaeA plant family of the order Celastrales, subclass Rosidae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID193405
CHEMBL ID2262843
CHEBI ID3456
MeSH IDM0388166

Synonyms (10)

Synonym
5227-24-7
cassine
12-(5-hydroxy-6-methylpiperidin-2-yl)dodecan-2-one
AC1L4W78 ,
AC1Q5CI5 ,
CHEMBL2262843
chebi:3456 ,
12-[(2s,5r,6r)-5-hydroxy-6-methyl-2-piperidyl]dodecan-2-one
Q5756672
DTXSID90966641

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Increased patient awareness about safe usage is important as well as more training with regards to traditional medicine."( Anti-staphylococcal, anti-HIV and cytotoxicity studies of four South African medicinal plants and isolation of bioactive compounds from Cassine transvaalensis (Burtt. Davy) codd.
Aiyegoro, OA; Mthethwa, NS; Obi, LC; Oyedeji, BA, 2014
)
0.61
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
citraconoyl group
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1419048Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Leishmania amazonensis PH8 promastigotes2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Isolation, leishmanicidal evaluation and molecular docking simulations of piperidine alkaloids from Senna spectabilis.
AID1419046Leishmanicidal activity against Leishmania amazonensis PH8 promastigotes after 48 hrs by spectrophotometric analysis2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Isolation, leishmanicidal evaluation and molecular docking simulations of piperidine alkaloids from Senna spectabilis.
AID1419047Cytotoxicity against African green monkey Vero cells after 48 hrs by resazurin dye-based spectrophotometric analysis2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Isolation, leishmanicidal evaluation and molecular docking simulations of piperidine alkaloids from Senna spectabilis.
AID1419049Leishmanicidal activity against Leishmania major MHOM/SU/1973/5-ASKH promastigotes after 48 hrs by cell counting method2018Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
Isolation, leishmanicidal evaluation and molecular docking simulations of piperidine alkaloids from Senna spectabilis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (30.77)29.6817
2010's8 (61.54)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.02 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index107.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]